S-W Oh1, S-K Myung, J Y Park, C M Lee, H T Kwon. 1. Department of Family Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul.
Abstract
BACKGROUND: Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer. Previous observational studies have reported inconsistent findings on this issue. We investigated the association between aspirin use and risk for lung cancer by conducting a meta-analysis. PATIENTS AND METHODS: Relevant studies were identified by searching Medline, EMBASE, and Cochrane Library to December 2009. We also reviewed relevant bibliographies from the retrieved articles. Two authors independently extracted data and assessed study quality. Disagreements were resolved by consensus. RESULTS: Fifteen studies (six case-control studies and nine prospective cohort studies) were included in the final meta-analysis. When all studies were pooled, the odds ratio (OR) of aspirin use for lung cancer risk was 0.86 [95% confidence interval (CI) 0.76-0.98]. In subgroup meta-analyses, there was no association between aspirin use and lung cancer risk among cohort studies (relative risk, 0.97; 95% CI 0.87-1.08), while there was a significant association among case-control studies (OR, 0.74; 95% CI 0.57-0.99). In a subgroup meta-analysis by quality of study methodology, a significant protective effect of aspirin use on lung cancer was observed only among eight low-quality studies (OR, 0.82; 95% CI 0.68-0.99), but not among seven high-quality studies (OR, 0.90; 95% CI 0.76-1.07). CONCLUSIONS: Overall, the findings of this meta-analysis support that there was no association between aspirin use and lung cancer risk. Our findings should be confirmed in future prospective cohort studies or randomized, controlled trials.
BACKGROUND:Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer. Previous observational studies have reported inconsistent findings on this issue. We investigated the association between aspirin use and risk for lung cancer by conducting a meta-analysis. PATIENTS AND METHODS: Relevant studies were identified by searching Medline, EMBASE, and Cochrane Library to December 2009. We also reviewed relevant bibliographies from the retrieved articles. Two authors independently extracted data and assessed study quality. Disagreements were resolved by consensus. RESULTS: Fifteen studies (six case-control studies and nine prospective cohort studies) were included in the final meta-analysis. When all studies were pooled, the odds ratio (OR) of aspirin use for lung cancer risk was 0.86 [95% confidence interval (CI) 0.76-0.98]. In subgroup meta-analyses, there was no association between aspirin use and lung cancer risk among cohort studies (relative risk, 0.97; 95% CI 0.87-1.08), while there was a significant association among case-control studies (OR, 0.74; 95% CI 0.57-0.99). In a subgroup meta-analysis by quality of study methodology, a significant protective effect of aspirin use on lung cancer was observed only among eight low-quality studies (OR, 0.82; 95% CI 0.68-0.99), but not among seven high-quality studies (OR, 0.90; 95% CI 0.76-1.07). CONCLUSIONS: Overall, the findings of this meta-analysis support that there was no association between aspirin use and lung cancer risk. Our findings should be confirmed in future prospective cohort studies or randomized, controlled trials.
Authors: Sebastiano La Maestra; Francesco D'Agostini; Alberto Izzotti; Rosanna T Micale; Luca Mastracci; Anna Camoirano; Roumen Balansky; James E Trosko; Vernon E Steele; Silvio De Flora Journal: Carcinogenesis Date: 2015-10-13 Impact factor: 4.944
Authors: Theodore M Brasky; Christina S Baik; Christopher G Slatore; John D Potter; Emily White Journal: Lung Cancer Date: 2012-05-17 Impact factor: 5.705
Authors: Ying Zhu; Yongyue Wei; Ruyang Zhang; Xuesi Dong; Sipeng Shen; Yang Zhao; Jianling Bai; Demetrius Albanes; Neil E Caporaso; Maria Teresa Landi; Bin Zhu; Stephen J Chanock; Fangyi Gu; Stephen Lam; Ming-Sound Tsao; Frances A Shepherd; Adonina Tardon; Ana Fernández-Somoano; Guillermo Fernandez-Tardon; Chu Chen; Matthew J Barnett; Jennifer Doherty; Stig E Bojesen; Mattias Johansson; Paul Brennan; James D McKay; Robert Carreras-Torres; Thomas Muley; Angela Risch; Heunz-Erich Wichmann; Heike Bickeboeller; Albert Rosenberger; Gad Rennert; Walid Saliba; Susanne M Arnold; John K Field; Michael P A Davies; Michael W Marcus; Xifeng Wu; Yuanqing Ye; Loic Le Marchand; Lynne R Wilkens; Olle Melander; Jonas Manjer; Hans Brunnström; Rayjean J Hung; Geoffrey Liu; Yonathan Brhane; Linda Kachuri; Angeline S Andrew; Eric J Duell; Lambertus A Kiemeney; Erik Hfm van der Heijden; Aage Haugen; Shanbeh Zienolddiny; Vidar Skaug; Kjell Grankvist; Mikael Johansson; Penella J Woll; Angela Cox; Fiona Taylor; Dawn M Teare; Philip Lazarus; Matthew B Schabath; Melinda C Aldrich; Richard S Houlston; John McLaughlin; Victoria L Stevens; Hongbing Shen; Zhibin Hu; Juncheng Dai; Christopher I Amos; Younghun Han; Dakai Zhu; Gary E Goodman; Feng Chen; David C Christiani Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-01-30 Impact factor: 4.254
Authors: Theodore M Brasky; Jingmin Liu; Emily White; Ulrike Peters; John D Potter; Roland B Walter; Christina S Baik; Dorothy S Lane; JoAnn E Manson; Mara Z Vitolins; Matthew A Allison; Jean Y Tang; Jean Wactawski-Wende Journal: Int J Cancer Date: 2014-03-20 Impact factor: 7.396